Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 1997

View Archived Issues

DuPont Merck receives FDA approval for nuclear imaging breast cancer test

Positive efficacy profile reported for Zonagen's Vasomax

Preliminary results from phase I trial of Nortran's RSD-921 reported

Meridian receives approval to market its E. coli detection kit in Japan

Monarch acquires ocular therapy from Glaxo Wellcome

Biomira notified of patent allowance for Theratope

Eisai develops agents for brain cancer

Inhibitors of IL-1beta/IL-6 production from Taisho

Daiichi reports compounds for RA, allergy and transplant rejection

Antiemetics described by Dainippon

Yamanouchi discloses Na+/H+ exchange inhibitors

New agents for atherosclerosis from Bayer

Antifibrotic agents claimed by Hoechst

Hoechst discloses agents for immune/autoimmune and other disorders

Anxiolytic/nootropic agents from Asahi

Therapeutic strategies for treating disorders of gastric emptying reported at DDW

New antidiarrheal agent reported at DDW

French scientists study role of tachykinins in colitis

MF-59 adjuvant enhances immunogenicity of HBV vaccine

New developments in chemotherapy reported at DDW

Oxis International moves IBD therapy to phase II

New medicines under development for IBD reported at DDW

Carvedilol approved by FDA for CHF

Gilead's oral influenza drug enters phase II

New immunomodulator from Orion with potential in IBD

Janssen characterizes new enterokinetic agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...